Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 29, 2024 at 11:11 am EST

New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin Portfolio to Meet the Needs of People Living with CIDP



Approval Supported by Phase 3...

Related Keywords

Canada ,Japan ,United States ,Mamatha Pasnoor ,Richard Ascroft ,Demyelinating Polyneuropathy ,Takeda Pharmaceutical Company Limited ,University Of Kansas Medical Center ,Department Of Neurology ,Foundation International ,European Medicines Agency ,Drug Administration ,Exchange Commission ,Derived Therapies Business ,Rasch Built Overall Disability Scale ,Kansas Medical ,Recombinant Human Hyaluronidase ,Inflammatory Neuropathy Cause ,Primary Humoral Immunodeficiency ,Multifocal Motor Neuropathy ,Chronic Inflammatory Demyelinating Polyneuropathy ,Primary Immunodeficiency ,Meningitis Syndrome ,Related Acute Lung Injury ,Infectious Agents ,Lab Tests ,Localized Infection ,Specific Populations ,Looking Statements ,Annual Report ,Markets ,